Global Swab and Viral Transport Medium Market to Reach USD 2.2 Billion by 2030 on Back of COVID-19 Pandemic
|
By LabMedica International staff writers Posted on 03 Dec 2020 |
|
Illustration
The global swab and viral transport medium (VTM) market was valued at USD 0.9 billion in 2019 and will witness a moderate growth rate of ~3% from 2020 to 2030 to reach USD 2.2 billion by 2030, driven by the onslaught of COVID-19 and increasing R&D activities.
These are the latest findings of Transparency Market Research (Albany NY, USA), a next-generation market intelligence provider.
The demand for swab and VTM has increased during the COVID-19 (coronavirus) pandemic. Since research institutes and labs have intensified their experiments for developing COVID-19 vaccines, companies in the swab and VTM market have increased their production capacities to develop products useful for viral collection, maintenance, and culture.
In terms of product, the transport medium segment accounted for a major share of the global swab and VTM market in 2019. The segment is anticipated to record a high CAGR during the forecast period, owing to rise in the need and demand for detection and prevention of the infectious diseases across the world. Geographically, North America accounted for a significant share of the global swab and VTM market in 2019. The presence of key players and growth strategies adopted by these players are the major factors driving the swab and VTM market in the region. The growth of the swab and VTM market in North America can also be attributed to rise in prevalence of infectious diseases. On the other hand, the Asia Pacific market is likely to grow at a rapid pace during the forecast period.
The COVID-19 pandemic has led to an unprecedented need of diagnostic reverse transcription-PCR (RT-PCR) testing. The ideal way for taking the specimen type is a nasopharyngeal (NP) swab, which can be easily transported to a molecular microbiology laboratory in VTM and the swabs for the further examinations. An increase in the demand for swabs and VTM owing to the COVID-19 pandemic is projected to drive the global swab and VTM market in the near future.
However, some factors are hampering the overall development of the global swab and VTM market, such as the increasing number of false negatives and re-infection of COVID-19 diagnosis. As such, healthcare professionals are facing issues to test performance and interpretation of COVID-19 testing, as the level of viral RNA in many cases is below the limit of detection. Hence, manufacturers in the swab and VTM market are following CDC guidelines to develop products that facilitate appropriate specimen collection.
Related Links:
Transparency Market Research
These are the latest findings of Transparency Market Research (Albany NY, USA), a next-generation market intelligence provider.
The demand for swab and VTM has increased during the COVID-19 (coronavirus) pandemic. Since research institutes and labs have intensified their experiments for developing COVID-19 vaccines, companies in the swab and VTM market have increased their production capacities to develop products useful for viral collection, maintenance, and culture.
In terms of product, the transport medium segment accounted for a major share of the global swab and VTM market in 2019. The segment is anticipated to record a high CAGR during the forecast period, owing to rise in the need and demand for detection and prevention of the infectious diseases across the world. Geographically, North America accounted for a significant share of the global swab and VTM market in 2019. The presence of key players and growth strategies adopted by these players are the major factors driving the swab and VTM market in the region. The growth of the swab and VTM market in North America can also be attributed to rise in prevalence of infectious diseases. On the other hand, the Asia Pacific market is likely to grow at a rapid pace during the forecast period.
The COVID-19 pandemic has led to an unprecedented need of diagnostic reverse transcription-PCR (RT-PCR) testing. The ideal way for taking the specimen type is a nasopharyngeal (NP) swab, which can be easily transported to a molecular microbiology laboratory in VTM and the swabs for the further examinations. An increase in the demand for swabs and VTM owing to the COVID-19 pandemic is projected to drive the global swab and VTM market in the near future.
However, some factors are hampering the overall development of the global swab and VTM market, such as the increasing number of false negatives and re-infection of COVID-19 diagnosis. As such, healthcare professionals are facing issues to test performance and interpretation of COVID-19 testing, as the level of viral RNA in many cases is below the limit of detection. Hence, manufacturers in the swab and VTM market are following CDC guidelines to develop products that facilitate appropriate specimen collection.
Related Links:
Transparency Market Research
Gold Member
SARS-CoV-2 Reactive & Non-Reactive Controls
Qnostics SARS-CoV-2 Typing
Japanese Encephalitis Test
Japanese Encephalitis Virus Real Time PCR Kit
Electrolyte Analyzer
CBS-4000 (CBS-400)
Latest COVID-19 News
- New Immunosensor Paves Way to Rapid POC Testing for COVID-19 and Emerging Infectious Diseases
- Long COVID Etiologies Found in Acute Infection Blood Samples
- Novel Device Detects COVID-19 Antibodies in Five Minutes
- CRISPR-Powered COVID-19 Test Detects SARS-CoV-2 in 30 Minutes Using Gene Scissors
- Gut Microbiome Dysbiosis Linked to COVID-19
- Novel SARS CoV-2 Rapid Antigen Test Validated for Diagnostic Accuracy
- New COVID + Flu + R.S.V. Test to Help Prepare for `Tripledemic`
- AI Takes Guesswork Out Of Lateral Flow Testing
- Fastest Ever SARS-CoV-2 Antigen Test Designed for Non-Invasive COVID-19 Testing in Any Setting
- Rapid Antigen Tests Detect Omicron, Delta SARS-CoV-2 Variants
- Health Care Professionals Showed Increased Interest in POC Technologies During Pandemic, Finds Study
- Set Up Reserve Lab Capacity Now for Faster Response to Next Pandemic, Say Researchers
- Blood Test Performed During Initial Infection Predicts Long COVID Risk
- Low-Cost COVID-19 Testing Platform Combines Sensitivity of PCR and Speed of Antigen Tests
- Finger-Prick Blood Test Identifies Immunity to COVID-19
- Quick Test Kit Determines Immunity Against COVID-19 and Its Variants
Channels
Clinical Chemistry
view channel
New Machine-Learning Equation Improves LDL Cholesterol Assessment
Accurate assessment of low-density lipoprotein (LDL) cholesterol is central to cardiovascular risk management, yet calculation methods can underestimate values in some patients. Laboratories widely use... Read more
Blood Biomarker May Signal Cognitive Decline Risk a Decade Before Symptoms
Accurately identifying which cognitively healthy older adults will later develop impairment due to Alzheimer’s disease remains difficult, as brain scans and genetic testing provide only part of the risk picture.... Read more
Molecular Diagnostics
view channel
Point-of-Care Molecular Technology Promises Transformative Shift in Oncology
Delays in obtaining molecular test results can hinder timely oncology decisions and widen disparities for patients far from centralized laboratories. Prolonged waits may also heighten anxiety and increase... Read more
New Test Delivers Four Prenatal Genetic Screens from One Blood Sample
Prenatal genetic screening often requires multiple tests, blood draws, and follow-up appointments, delaying access to clinically relevant information. Early, consolidated insights may help clinicians coordinate... Read more
Multiplex PCR Test Differentiates Four Causes of Ulcerative Skin Lesions
Vesicular and pustular skin lesions can stem from multiple viral pathogens, complicating timely diagnosis and management. Sequential single-pathogen testing can miss infections when the causative agent... Read more
Blood Test Guides Patient Selection for Radiopharmaceutical Therapy in Prostate Cancer
Radium-223 dichloride is a bone-targeted radiopharmaceutical therapy that improves overall survival and quality of life for many patients with metastatic castration-resistant prostate cancer (mCRPC), but... Read moreHematology
view channel
New Marker Helps Detect Aggressive Multiple Myeloma Earlier
Multiple myeloma is an incurable malignancy of plasma cells and the second most common blood cancer worldwide, with more than 188,000 new cases each year. Although therapies have advanced, most patients... Read more
New Biomarkers Predict Resistance to Targeted Therapy in Rare Blood Cancer
Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare and aggressive leukemia with limited treatment options and a poor prognosis. Although tagraxofusp is the first approved targeted therapy for... Read more
Immunology
view channel
Ultrasensitive Blood Test Detects Sjögren’s Signature Years Before Diagnosis
Sjögren’s disease is a common autoimmune condition that can be difficult to recognize early, leading to delayed diagnosis and persistent symptom burden. It affects around half a million people in the UK... Read more
New Assays Expand Cytokine Testing for Transplant and Immunocompromised Patients
Eurofins Viracor has introduced three plasma-based assays—CXCL9 (Test Code 33607), CXCL10 (Test Code 33609), and interleukin-18 (IL-18) (Test Code 33611)—expanding its immunology testing menu for transplant... Read more
Microbiology
view channel
Syndromic GI Panel Detects Cyclospora for Rapid Case Confirmation
U.S. health authorities have reported a rapid increase in cyclosporiasis since May 2026, with more than 1,600 confirmed infections and thousands of additional suspected cases under investigation.... Read more
Rapid Panel Identifies Gram-Negative Pathogens and Resistance Markers in Bloodstream Infections
Bloodstream infections require rapid identification of causative pathogens and resistance mechanisms to guide effective therapy. Delays in profiling gram-negative organisms, which are frequently associated... Read more
Pathology
view channel
Digital Pathology Tool Predicts Breast Cancer Outcomes and Therapy Response
Breast cancer prognosis often depends on microscopic assessment of tumor architecture, a process that can be subjective and lead to variable predictions across patient groups. Quantitative measures that... Read more
AI Bone Marrow Mapping Provides New Tool to Track Blood Cancer Severity
Myelodysplastic neoplasms, a group of blood cancers that primarily affect older adults, are challenging to stage and monitor, often requiring repeated bone marrow biopsies that can yield uncertain interpretations.... Read more
Technology
view channel
Training Device Improves Accuracy of Pooled Molecular Diagnostics
High-throughput molecular diagnostics have transformed infectious disease detection, but many workflows remain difficult to execute accurately without extensive training. Sample pooling can cut per‑test... Read more
New CE-Certified Software Advances Whole-Genome Cancer Testing
European hospitals are increasingly using comprehensive tumor genomics to guide therapy, but routine whole genome sequencing (WGS) requires validated, regulation-compliant workflows. A newly CE-certified... Read more
National Rare Disease Registry Standardizes Genetic and Clinical Data for Coordinated Care
Rare diseases collectively impose a significant clinical burden despite their individual rarity, often involving multisystem presentations and prolonged diagnostic journeys. Limited specialist expertise... Read more
Industry
view channel
Tempus to Acquire Personalis in $1.5 Billion Precision Oncology Deal
Tempus AI, Inc. (Chicago, IL, USA) has entered into a definitive agreement to acquire Personalis, Inc. (Fremont, CA, USA), expanding its capabilities in molecular residual disease (MRD) testing and cancer... Read more
